The cure of childhood acute lymphoblastic leukemia (ALL) was a momentous achievement in the history of medicine. It demonstrated that widely disseminated cancers can be eradicated with cytotoxic drugs, and it illustrated the power of systematic laboratory studies and randomized clinical trials applied to a single disease. As ALL cure rates edge towards 80%, several key challenges are apparent. First, it will be important to devise more effective therapies for the high-risk patients who continue to relapse on contemporary protocols. Second, better methods of disease assessment and treatment are needed to avoid relapses that still occur in so-called low-and intermediate-risk groups. Third, the persistence of late adverse effects due to radiation and certain genotoxic agents, such as the anthracycline compounds and the epipodophyllotoxins, mandates the development of alternative therapies that are both safe and effective in children. The International Childhood ALL Workshop, held 3-4 December 1997, at St Jude Children's Research Hospital in Memphis, Tennessee, brought together leading experts in leukemia therapy to discuss progress in meeting these and other challenges, and to suggest directions for future studies. The participants, from 12 co-operative study groups and two individual centers, were welcomed by Dr A Nienhuis (St Jude Director), who provided the historical context for the workshop, and by Drs W Evans and C-H Pui, the meeting coorganizers.
Clinical trial updates
AIEOP Dr G Masera (Italian Association of Pediatric HematologyOncology and International Berlin-Frankfurt-Mü nster Study Group) reviewed the Italian experience in treating ALL patients by BFM-type strategies. The AIEOP trials have secured excellent control of CNS leukemia with use of intensive intrathecal treatment and effective systemic chemotherapy; currently, only 15% of patients, mainly those with T cell ALL and leukocyte counts Ͼ100 × 10 9 /l, are given prophylactic CNS irradiation. Dr Masera cautioned that although treatment results of the AIEOP were comparable to those of other major study groups, there was an unacceptably high frequency of brain tumors among high-risk patients receiving 1800 cGy cranial irradiation (about 50 times that among unirradiated patients). He also stressed the inadequacy of therapy for highrisk subgroups with unique therapeutic requirements, including patients with the Philadelphia (Ph) chromosome, the t(4;11) translocation or age younger than 1 year. One alternative he suggested would be to apply prospective meta-analysis techniques on an international scale to identify treatments that could be effective against ALL resistant to conventional agents. While generally agreeing with this concept, Dr Malcolm Smith (National Cancer Institute, USA) reiterated some of the shortcomings of meta-analysis, which has proved notoriously imprecise when applied to widely diverse groups.
ANZ group
Dr K Waters (Australian and New Zealand Children's Cancer Group ALL Trials) outlined progress in clinical trials of CCGtype therapy within Australia and New Zealand. The overall event-free survival estimate in ANZ study V was 68%. The subsequent study was designed to determine if the addition of a delayed intensification phase at 40 weeks post-remission would improve clinical outcome overall. Erwinia asparaginase instead of E. coli preparation was used in this study in an attempt to decrease toxicities. The event-free survival estimate at 4 years in ANZ study VI (for all patients) was 56%. Thus far, there has been no indication of a clinical benefit from the delayed intensification treatment. The inferior outcome in study VI compared to study V was attributed to the use of Erwinia asparaginase, which has a shorter half-life (0.65 days) than the E. coli derivative (1.24 days). One contributor emphasized the value of such experience, pointing out that it illustrates how seemingly 'minor' modifications of a complex protocol can lead to a worse result overall. Another contributor suggested that a comparable outcome might be achieved if the dosing and scheduling of different forms of asparaginase were based on their pharmacokinetics and pharmacodynamics; that is, the agent with the shorter half-life should be given more frequently. Future ANZ trials will likely test the reliability of MRD detection on day 35 as the basis for treatment intensification or continuation of standard therapy.
BFM group
A recurring theme of the workshop was that rapid and repeated reduction of leukemic cell populations can prevent the emergence of drug-resistant clones -an ALL treatment strategy pioneered by the Berlin-Frankfurt-Mü nster Study Group. Since 1970, the German investigators have enrolled a total of 4918 patients in randomized clinical trials, with a collective event-free survival of 68%. Dr M Schrappe (BFM ALL Trials) reviewed the major questions that have been addressed by this group over the past two decades, including the optimal duration of therapy, the importance of remission reinduction treatment, the prognostic impact of early responses to treatment, and the feasibility of reducing CNS irradiation.
In the BFM 81 and 83 trials, 18 months of continuation treatment yielded a poorer outcome than did treatment for 24 months, and prednisone and vincristine pulses emerged as important components of multidrug regimens for ALL. In both the BFM 83 and 86 studies, reinduction treatment improved long-term outcome for standard-risk cases. Dr Schrappe emphasized the lack of recent progress in treating high-risk leukemias. He called attention to cases in which the blast cells show a poor initial in vivo response to prednisone and one intrathecal methotrexate (MTX) injection (у1000 cells/l circulating blasts after 7 days of treatment), noting that only 35% of patients with this feature have become long-term event-free survivors, despite greater use of bone marrow transplantation. Since the initial steroid response appears to identify a quite different subset of patients than do clinical, cytogenetic or molecular markers (eg only one-third of Ph+ patients are poor responders to prednisone), he suggested that this marker might be used to simplify the complex risk assessment strategies now in place at most centers. To this end, Dr Schrappe reminded participants that the largest number of relapses still occur in patients judged to have a low or standard risk of failure.
In the BFM 90 study, despite the reduction of anthracycline and cranial irradiation treatment, the event-free survival estimate at 5.8 years for all patients showed a modest increase, to 78%, which was attributed partly to the very low CNS relapse rate (2.9% isolated and combined). It may be important that 12 Gy cranial irradiation appeared to be adequate treatment for subclinical CNS involvement, even in high-risk cases. In the BFM 95 study, cranial irradiation is limited to the 15 to 20% of patients with T cell or high-risk ALL.
Brazilian group
The presentation by Dr S Brandalise (Brazilian Cooperative ALL Group) illustrated how a successful ALL treatment program can be devised and implemented in a developing country. Using a five-agent induction regimen that included cytarabine intensification for high-risk patients, and high-dose methotrexate (HDMTX) consolidation and reinduction treatment for all patients, the GBTL1-ALL-93 study achieved a 3-year event-free survival of 90%, which compared very favorably with other findings presented at the workshop. Dr V Odone reported on a second Brazilian study (LLA-PROP-90) that also featured high-dose cytarabine intensification for high-risk patients; this study likewise produced an excellent outcome, with an overall event-free survival of 86% at 3 years. A detailed prognostic factor analysis was not possible due to the purely clinical approach to risk assessment taken by the Brazilian investigators, who must contend with restricted budgets for laboratory procedures.
CCG
A major theme of the presentation by Dr P Gaynon (Children's Cancer Group, USA) was that non-high-risk patients can benefit from treatment intensification as much as (if not more than) high-risk patients. Indeed, in the CCG-1881 study, introduction of a late intensification phase (modeled on BFM protocol II) boosted long-term event-free survival among lower-risk patients from 79 to 85%, with day-14 marrow responders showing the greatest gain from this modification. The substitution of dexamethasone for prednisone has significantly reduced the CNS rate at 3 years (3.1 ± 0.8% vs 7.1 ± 1.2%) and boosted the overall event-free survival estimate (91 ± 1% vs 86 ± 2%) in a randomized trial of children with lower-risk ALL. Double intensification (two treatments with protocol II) in average-risk patients in the CCG-1891 study led to an increase in event-free survival, from 75 to 84%, at 5 years of follow-up. The value of double intensification given in a timely fashion was established in the CCG-1882 study, in which patients with a slow early response to remission induction were randomized to receive this 'augmented' therapy or standard postinduction chemotherapy. The 4-year event-free survival was significantly better in the augmented arm than in the standard arm (75.4 ± 4.0% vs 57.2 ± 4.5%). Dr Gaynon also stressed that, provided intensive systemic therapy is used, intrathecal MTX given from the start of treatment through the maintenance phase is equivalent to 1800 cGy of cranial irradiation in average-risk patients younger than 10 years of age.
He concluded by reviewing what he called 'the failures' of CCG and perhaps those of the field in general. Near the top of the list was the relative lack of attention to patients in relapse, a subgroup larger than the national cohort of Wilms' tumor patients. He also lamented attempts to compare the results of highly complex regimens when it is virtually impossible to identify the component or components responsible for any observed differences. To Dr Gaynon, the proliferation of numerous small pilot studies testing treatments for biologically defined patient subgroups is a disturbing trend. It would be better, he argued, to concentrate on randomized studies with the statistical power to answer study questions definitively, even if long accrual periods are required, a view shared by a number of participants.
Dana-Farber group
Dr S Sallan (Dana-Farber Cancer Institute, Boston) reminded the workshop that 'we're all essentially in the same place with respect to survival curves and we need to remember that more (therapy) is not necessarily better'. With that comment, he described Dana-Farber studies in which hyperfractionated radiation was being tested as a possible substitution for standard methods of radiation treatment. The early results suggest no loss of efficacy with hyperfractionated doses, but substantially fewer instances of growth retardation. In efforts to ameliorate the cardiotoxicity associated with doxorubicin therapy, his group has shown that continuous infusions of this agent offer no cardioprotection by comparison to standard bolus doses. However, in a retrospective analysis, they identified 300 mg/m 2 as a safe cumulative dose. Dr Sallan elaborated on the theme of 'more is not necessarily better' by reviewing studies in which leukemic lymphoblasts were rendered immunogenic by inducing expression of the B7 antigen. This achievement, he contended, may set the stage for adoptive immunotherapy of ALL. More provocative still was a recent series of experiments he described, in which investigators in Dr Judah Folkman's laboratory (Children's Hospital, Boston) were able to demonstrate that ALL has a distinct angiogenic component, suggesting the potential utility of antiangiogenic agents in leukemia therapy. Indeed, the Boston team subsequently used an angiogenesis inhibitorendostatin -to cure mice of B-lineage leukemia. This finding, Dr Sallan emphasized, has broad implications for future clinical trials in ALL and should be pursued vigorously by leukemia researchers worldwide.
DCLSG
Drs W Kamps and A Veerman (Dutch Childhood Leukemia Study Group) summarized preliminary results of their recent DCLSG-ALL-8 study, in which addition of high-dose l-asparaginase (20 weekly doses) or intravenous high-dose 6-mercaptopurine (four doses over 8 weeks) during continuation treatment failed to improve clinical outcome for standard-risk or medium-risk patients, respectively. By contrast, substitution of dexamethasone for prednisone significantly improved treatment outcome of a group of non-high-risk patients (71% of the total) in an earlier Dutch trial (DCLSG-ALL-6), yielding an 8-year event-free survival of 81 ± 3% (s.e.). In vitro drug sensitivity to prednisone, vincristine, daunorubicin and l-asparaginase, based on results of the MTT assay, showed independent prognostic significance in study 8 and therefore will be considered for use in risk classification in the upcoming DCLSG trial.
EORTC group
In the afternoon session, Dr J Otten (European Organization for Research and Treatment of Cancer, Children's Leukemia Cooperative Group) described results of a recent clinical trial testing the value of Erwinia vs E. coli l-asparaginase, the addition of intravenous high-dose 6-mercaptopurine and, for high-risk patients, the addition of two doses of cytarabine at 1 g/m 2 . The treatment backbone was a BFM-type regimen. Although the E. coli-derived enzyme showed a clear therapeutic advantage, whether event-free or overall survival was used as the end-point, neither cytarabine nor intravenous 6-mercaptopurine had clinical benefit. To the contrary, the latter apparently had a detrimental effect on outcome, especially in boys receiving Erwinia l-asparaginase. EORTC investigators are currently evaluating the efficacy of dexamethasone during remission induction, as well as extended use of l-asparaginase during remission induction and consolidation treatment. Ultimately, they intend to use minimal residual disease (MRD) detection during the immediate post-remission period to identify the occasional standard-risk patient who may benefit from intensified treatment. The session moderator, Dr H Gadner (BFM) cautioned participants against using a single quantitative measure of drug resistance to modify therapy. A better strategy, in his opinion, would be to combine MRD detection with early prednisone responsiveness.
FRALLE group
The FRALLE 93 study (French Acute Lymphoblastic Leukemia Collaborative Group) reported by Dr G Schaison, tested a series of risk-based modifications in an otherwise BFM-like protocol. The questions posed were whether or not HDMTX is superior to standard-dose MTX in good-risk patients, whether idarubicin can be used in place of daunorubicin in patients with an intermediate risk of relapse, and whether granulocyte colony-stimulating factor (G-CSF) confers a therapeutic advantage in patients with a very high risk of failure. Results to-date indicate no advantage for HDMTX in children with a favorable prognosis, nor was idarubicin a useful substitute for daunorubicin in therapy for intermediate-risk patients. Finally, although G-CSF did shorten periods of neutropenia in highrisk patients, this effect did not translate into improved eventfree survival, in agreement with published results from the Mayo Clinic and St Jude Hospital. A controversial observation in the FRALLE study was the lack of any prognostic influence by the TEL-AML1 fusion gene among B cell precursor ALL cases.
NOPHO
The Nordic Society for Paediatric Hematology and Oncology -including Iceland, Norway, Finland, Sweden and Denmark -is one of the few groups that has prospectively tested the clinical significance of MRD detection. In the NOPHO MRD-95 study, presented by Dr K Schmiegelow, specific clonal IgH and TCR gene rearrangements were used to identify cases with MRD on day 29 of remission induction therapy. Preliminary analyses revealed an event-free survival of 96% for patients without MRD on day 29 and 36% for those with a positive finding, supporting the prediction that such measurements would be a useful guide for early treatment intensification.
In a second innovative study (NOPHO ALL-92), the Scandinavian group sought to improve maintenance chemotherapy by evaluating the adjustment of MTX and 6-mercaptopurine doses according to white blood cell count and cellular levels of MTX polyglutamates and 6-thioguanine nucleotides. The 4-year event-free survival in the study was 88 ± 2% (s.e.); the result for all patients treated consecutively in the Nordic countries during the same time period was 78%. Although the cellular level of 6-thioguanine nucleotides was the strongest prognostic factor, pharmacologically based modifications have not yielded a survival advantage.
POG
In contrast to co-operative groups that have focused on abolishing risk factors through greater treatment intensification, the USA's Pediatric Oncology Group (POG) has attempted to define the minimal therapy that can be administered to a particular risk group without jeopardizing long-term outcome. As reported by Dr B Camitta (POG ALL Committee) this strategy has met with considerable success. Using the features of age 1-9 years, WBC Ͻ50 × 10 9 /l, DNA index Ͼ1.16, and trisomy of chromosomes 4 and 10, POG investigators have identified a very low-risk group (20% of all B cell precursor patients) whose 4-year event-free survival on standard antimetabolite therapy approaches 95%. Among standard-risk cases, highdose intravenous MTX yielded a better outcome than fractionated low-dose oral MTX, whereas high-dose intravenous 6-mercaptopurine failed to improve results. Dr Camitta acknowledged the difficulties faced by POG in boosting outcome for high-risk patients, urging greater collaboration among the international ALL treatment groups in the search for more effective therapy.
St Jude Children's Research Hospital
Three-to 10-fold differences in the rates of clearance of antileukemic drugs among children with ALL suggest that clinical outcome could be improved if one could individualize doses so that patients with fast clearance received adequate systemic drug exposures. This hypothesis was tested in the St Jude Total Therapy XII study, in which 182 patients were randomized to receive either conventional post-remission therapy or a regi-men in which doses of MTX, teniposide and cytarabine were increased in patients with rapid clearance and decreased in those with slow clearance. The study results, presented by Dr W Evans, showed an advantage for individualized dosing of MTX in patients with B-lineage ALL but not in those with a T cell immunophenotype, probably because the target range of systemic exposure was inadequate in the latter group. The time-dependent systemic exposure to MTX, but not teniposide or cytarabine, was significantly related to the risk of relapse in B-lineage ALL in this trial.
A major question raised by this report was whether a complex strategy of individualized MTX dosing would be practical in a co-operative group setting. Dr Evans pointed out that it is possible that similar results could be obtained by giving all B-lineage cases an MTX dose of 2.5 g/m 2 , which would ensure adequate systemic exposure even in patients with the most rapid drug clearance. Alternatively, in view of the low intrapatient variation in drug clearance, as compared with that of interpatient variation, it might be possible to use a single clearance estimate after the first dose to adjust subsequent doses in each patient.
The direction of upcoming St Jude clinical trials was presented by Dr C-H Pui. In Total Therapy study XIV, emphasis will be placed on clarifying the optimal dosage of MTX for various phenotypic and genotypic subgroups, early intensification of intrathecal therapy, double reinduction therapy for both standard-and high-risk patients, and the use of a novel system of risk assessment that integrates molecular, cytogenetic, immunologic and clinical presenting features.
Tokyo group
The report by Dr M Tsuchida (Tokyo CCG ALL Trial) illustrated the importance of extended maintenance therapy in children with a standard or intermediate risk of relapse. In the Japanese L92-13 study, which tested a BFM-like regimen, all patients were treated for 1 year only, regardless of their risk classification. The 4-year event-free survival estimate for highrisk patients, 60%, did not appear to suffer from the truncated period of maintenance therapy, perhaps because of early and repeated intensification phases with etoposide, cytarabine and l-asparaginase. On the other hand, both of the two lower-risk groups fared worse than average (60 and 54%, respectively), with boys having a significantly poorer outcome than girls. Dr Tsuchida attributed this result in part to an unexpectedly high rate of testicular relapse, most likely reflecting the abbreviated exposure to maintenance chemotherapy, which included two courses of HDMTX at 3 g/m 2 .
UKALL group
Dr T Eden (United Kingdom Medical Research Council ALL Trials) concluded the clinical trial updates by tracing the evolution of UKALL therapy from relatively nonaggressive regimens in the 1970s to more recent protocols that provide intensive treatment to all patients irrespective of risk status. In the UKALL X study (1985) (1986) (1987) (1988) (1989) (1990) , a four-way randomization to receive an intensification module at week 5, at week 20, at both time-points or not at all demonstrated a clear benefit for two courses (5-year event-free survival of 71% compared with 61 to 62% for other arms). Both standard-and high-risk patients benefited from this double intensification. The randomized UKALL XI (1990 XI ( -1997 study assessed the efficacy of various CNS-directed treatments based on the presenting leukocyte count (above or below 50 × 10 9 /l), and the potential therapeutic advantage of a third intensification block of therapy. Preliminary results show a reduction in isolated CNS relapses from 6 to 3% with HDMTX, but this outcome has not yet translated into a significant improvement in event-free or overall survival. The current trial, ALL 97, seeks to determine the efficacy of dexamethasone vs prednisone, 6-thioguanine vs 6-mercaptopurine and three intensification blocks as compared with two.
As the first session ended, participants were reminded by Dr Masera (AIEOP) that most of the progress being made in international ALL trials does not extend to underdeveloped countries. Indeed, in some isolated regions, 90% of children with ALL do not have access to any therapy for this disease. The real challenge, according to Dr Masera, is to devise treatment that can be made available, at minimal cost, to all children of the world.
Risk classification
The Holy Grail of leukemia therapy is a risk classification system that would allow investigators to match treatment with prognosis as closely as possible. This capability would not only avoid over-or undertreatment of individual patients, but would also increase the comparability of clinical trials, thus facilitating data-driven discussions among diverse study groups. As pointed out by Dr M Smith (National Cancer Institute, USA), the Rome/NIH consensus criteria, which are based solely on age and leukocyte count, have done much to foster greater uniformity of risk classification among international research groups; however, they suffer from the absence of biological factors, including molecular genetic changes and blast cell sensitivity to chemotherapy.
Dr A Biondi (International BFM Study Group) presented intriguing results suggesting that MRD testing on day 42 of remission induction could be used to segregate patients into prognostic groups based on the quantitative level of disease detection, as follows: no MRD: low risk (98% long-term eventfree survival); MRD at 10 −4 : intermediate risk (78%); and MRD at 10 −3 or higher: high risk (16%). Whether these groups are unique or merely duplicate those identified by more conventional markers, such as the initial leukocyte count and the early response to prednisone, remains to be determined. Dr A Barachel (FRALLE) introduced a new high-risk feature; that is, the presence of Ͼ25% bone marrow blasts at day 21 of remission induction, found in 3.9% of their patients.
Dr B Camitta (POG) emphasized the ability of certain lowrisk criteria (DNA index Ͼ1.16, trisomy of chromosomes 4 and 10, and the presence of a TEL gene rearrangement) to distinguish a subset of patients whose long-term event-free survival on antimetabolite therapy is 90% or better. Dr P Gaynon (CCG) expressed doubt over the value of extensive subgroup analyses as a means to improve treatment selection, preferring instead a single treatment-driven criterion (marrow response on day 7 or 14) to identify standard-risk patients in need of more intensive therapy.
Theoretically, if one knew the drug sensitivity of leukemic blasts at the time of diagnosis, it might be possible to dispense with most or all other prognostic factors. Results of an in vitro drug sensitivity assay (MTT), presented by Dr R Pieters (DCLSG), indicated the feasibility of this strategy in a clinical setting. Using relative sensitivity to vincristine, prednisone and l-asparaginase as the basis of risk classification, Dr Pieters and his colleagues identified a low-risk group (defined by sensitivity to all three agents, 20% of patients) with a 3-year eventfree survival rate of 100%, an intermediate-risk group (sensitivity to one or two agents, 40%) with a rate of 84%, and a high-risk group (poor sensitivity to all three agents, 40%) who had a rate of 43%. In a recently performed multivariate analysis, in vitro drug sensitivity was the only marker that retained prognostic significance after adjustment for competing covariates. Dr Evans noted that it would be important to determine whether in vitro drug resistance is highly correlated with a high percentage of blasts in day 7 or 14 bone marrow samples (in vivo resistance), as the latter is a feasible measurement at any treatment center.
Dr J Rubnitz (St Jude Children's Research Hospital) proposed an ambitious risk classification strategy, in which all T cell patients are regarded as having a standard risk of relapse, excluding those refractory to induction therapy, who are upgraded to high risk. Among patients with B cell precursor ALL, the high-risk group is defined by the BCR-ABL fusion gene in association with high leukocyte counts, MLL rearrangement (in infants) and failure to respond to induction therapy. Low-risk cases are identified on the basis of hyperdiploidy (Ͼ50 chromosomes), the TEL-AML fusion gene, age 1 to 9 years and a leukocyte count Ͻ50 × 10 9 /l, and a favorable early response to chemotherapy. All others are classified as standard risk. In the experience of the St Jude researchers, antimetabolite-based regimens are sufficient for low-risk leukemias, while standard-risk cases require intensive multiagent therapy. Patients with high-risk ALL are candidates for treatment intensifications with hematopoietic stem-cell transplantation.
Dr M Schrappe (BFM) reiterated a common complaint leveled at the Rome/NIH criteria: that the standard-risk group 'is not good enough' and the high-risk group 'is not bad enough'. Thus, by augmenting these guidelines with the early clinical response to prednisone and to one intrathecal MTX treatment, as well as several other easy-to-obtain prognostic indicators, the BFM investigators have reduced their high-risk group to only 10% of patients, while establishing a low-risk group that accounts for 55% of the total study population.
A number of contributors raised objections to the increasing complexity of risk classification systems, pointing out their impracticability in large co-operative trials and at centers with modest laboratory resources. MRD detection was of special concern because of fear that minimal levels of blast cells might have different meanings for different biological species of ALL and different treatment protocols. A consensus opinion was that the early clinical response to therapy has overriding importance in most patients, and when combined with Rome/NIH criteria, can provide a useful and reliable measure of prognosis. Some investigators felt that it would be easier and probably just as accurate to assess these responses in peripheral blood compared to bone marrow.
Treatment of very high-risk patients
The optimal treatment for infants, patients with MLL rearrangements or the Philadelphia chromosome, and those with poor early responses to therapy has been controversial. Dr R Pieters summarized data from the Dutch group indicating remarkable in vitro sensitivity of infant ALL to cytarabine, leading him to suggest that patients in this age group might benefit from treatment based on hybrid regimens containing both ALL-and AML-like treatment elements. Others, including Drs B Camitta (POG) and T Eden (UKALL), reported improved event-free survival rates for infants treated on intensified chemotherapy for ALL, but the results still had not surpassed 50% at 4 years of follow-up. The participants agreed that infants with MLL rearrangements, hyperleukocytosis and a CD10 − immunophenotype have an especially dire prognosis and should be considered candidates for allogeneic stem cell transplantation or other experimental therapies. Dr P Gaynon argued strongly that infants should be managed on separate protocols because of their unique logistical and supportive care requirements.
Considerable debate was stimulated by the St Jude finding, presented by Dr G Rivera, that children with a BCR-ABL fusion gene and a leukocyte count of less than 25 × 10 9 /l can be cured with intensive chemotherapy alone (4-year eventfree survival rate, 73 ± 19% s.e.). Most participants reported little or no success in treating Ph+ ALL with intensive chemotherapy without hematopoietic stem cell rescue, regardless of the presenting white count. An exception was a joint AIEOP and BFM study in which a 40% long-term event-free survival rate was obtained after treatment with chemotherapy alone in the two-thirds of Ph + patients with an adequate prednisone response on day 8. Dr B Camitta said that POG studies had also confirmed the prognostic value of presenting white blood counts in Ph + ALL patients. Although few participants reported outcome data on older patients with MLL gene rearrangements, the consensus was that most of these patients fare poorly on conventional chemotherapy and require alternative treatment. There were no claims of successful salvage therapy for children who failed induction treatment, leading more than one contributor to suggest that these patients should be regarded as prime candidates for innovative experimental therapies.
CNS-directed therapy
The question raised by Drs G Masera and L Kun at the opening of this session ('Who needs cranial irradiation and what is the appropriate dosage?') concisely identified the key issue in current approaches to CNS-directed therapy. Although investigators concur that advances in systemic chemotherapy and intrathecal medications have generally eliminated the need for cranial irradiation in children with ALL, there remains concern over the hazard of CNS relapse in certain high-risk groups. Dr B Camitta reported that the POG has eliminated cranial irradiation in all of its B cell precursor ALL patients without loss of efficacy. However, for T cell patients whose white counts exceed 50 × 10 9 /l, cranial irradiation is still combined with triple intrathecal chemotherapy. Dr P Gaynon (CCG) voiced the opinion that aggressive systemic therapy obviates the need for cranial irradiation in all subgroups except patients who have delayed responses to induction therapy.
To define a quantitative basis for intensification of CNSdirected therapy, St Jude investigators are testing the detection of leukocytes and blast cells in cerebrospinal fluid (CSF) at diagnosis, reserving cranial irradiation for patients with hyperleukocytosis or Ph + leukemia and those with five or more leukocytes per l of CSF with definable blast cells. This strategy, together with early intensive triple intrathecal treatment and effective systemic chemotherapy, has yielded a 1% overall rate of isolated CNS relapse and a 2% rate of CNS plus marrow relapse.
Some contributors reported a lack of prognostic significance for the presence of blast cells in CSF; however, the consensus was that such findings after three intrathecal treatments during remission induction are indeed ominous and warrant intensification of CNS-directed therapy. Dr M Schrappe (BFM) indicated that in the context of effective systemic therapy, 12 Gy of cranial irradiation is sufficient treatment for high-risk cases. Finally, Dr A Veerman (DCLSG) argued that with the use of dexamethasone, intensive intrathecal treatment and effective systemic chemotherapy, one can eliminate cranial irradiation altogether. This hypothesis is being tested in the current Dutch and UKALL 97 trials as well as the upcoming St Jude clinical trials.
The trend toward elimination of cranial irradiation in children with ALL was enthusiastically endorsed by all workshop participants, although many voiced concern over the potential neurotoxicity of intrathecally administered drugs. Unfortunately, only limited data were available to address this important issue. Preliminary results of the UKALL XI study showed no difference between HDMTX and intrathecal therapy in terms of psychometric outcome; however, both forms of treatment were associated with some deterioration of neuropsychologic function, as was CNS irradiation.
The closing comment, that ALL researchers must look beyond the limits of their personal and institutional goals and strive to extend curative therapy to 100% of children with ALL, could be taken as the ultimate challenge in the field and perhaps the one most worthy of vigorous pursuit.
